This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Feb 2021

WuXi Biologics, WuXi STA and Antengene collaborate to advance ADC candidate

The Wuxi companies will provide process development, scale-up, and GMP to advance Antengene's ADC program to clinical stage

WuXi Biologics, STA Pharmaceutical, and Antengene have formed a collaboration to accelerate the development and manufacturing of antibody-drug conjugate (ADC) drug candidates in Antengen’s pipeline.

This is the second partnership between Antengene and WuXi Biologics for the GMP manufacturing services following the announcement of a bispecific antibody contract development and manufacturing (CDMO) service collaboration in October 2020.

WuXi Biologics and WuXi STA will provide services for the process development, scale-up, and Good Manufacturing Practice (GMP) manufacturing of ADC drug intermediates.

Antengene will focus on the discovery and development of the monoclonal antibody, the core element of the ADC drug development.

WuXi STA (a CDMO) will focus on the GMP manufacturing of linkers and payloads whereas WuXi Biologics (a global company with open-access biologics technology platforms) will provide process development for monoclonal antibody and the biological conjugation as well as the subsequent GMP manufacture.

All three parties will work closely to reach the goal of accelerating the development of ADCs for the benefit of patients.

Dr Jay Mei, Founder, Chairman and CEO of Antengene, said he hoped that the combined expertise of the three companies will bring their ADC pipeline forward much faster.

Related News